🇺🇸 FDA
Pipeline program

Acoramidis (AG10)

AG10-304

Phase 3 small_molecule active

Quick answer

Acoramidis (AG10) for Amyloid Cardiomyopathy, Transthyretin-Related is a Phase 3 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BridgeBio Oncology Therapeutics
Indication
Amyloid Cardiomyopathy, Transthyretin-Related
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials